Daily dosing key to the efficacy of tenofovir-based HIV PrEP
New booklet from NAM: Taking your HIV treatment
No significant risk of resistance if HIV infection occurs during use of Truvada PrEP
Investigational protease inhibitor TMC310911 highly potent in phase 2 study
Early antiretroviral treatment reduces risk of AIDS and HIV-related illness
People living with HIV in the UK still have impaired health-related quality of life
Abolishing HIV in Rwanda
European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs
